Abstract:Background: In recent years, taxanes play an important role in chemotherapy of breast cancer patients, and its response rate is about 50%. Taxanes is primarily metabolized by CYP450 in liver microsome, and it also is a substrate for P-glycoprotein (the coded product of MDR1 gene). The interindividual heterogeneity in drug-metabolizing enzymes and transporters has contributed to the variability on anti-cancer efficacy of taxanes in breast cancer patients. Several studies showed that the pharmacokinetics of taxanes was influenced by the MDR1 polymorphisms. The aim of this study is to investigate the relationship between MDR1 gene polymorphisms and taxanes-based chemotherapy responses, and provides useful information for clinical personalized medicine and prognostic judgment. Material and Methods: Genotyping of MDR1 variants was determined in the blood samples from 142 Chinese Han patients with breast cancer, by PCR-RFLP. The association of the gene polymorphisms of MDR1 C1236T at exon 12, G2677T/A at exon 21 and C3435T at exon 26 with chemotherapy responses was analyzed on the 63 patients, who received taxanes-based neoadjuvant chemotherapy [56 cases with TA (taxanes and anthracycline), 7 cases with TAC (C: cyclophosphamide)] and had the intact treatment follow-up information. Results: In the 142 breast cancer patients, the frequencies of C1236T, G2677T, G2677A and C3435T variant alleles was 70.7%,52.1%,2.5% and 46.5%, respectively, and the frequency of 3435T allele was significantly higher in comparison with that in healthy subjects (34.7%). In the 63 patients with neoadjuvant chemotherapy, the overall clinical response rate (CR+PR) to chemotherapy was 66.7%. 3435TT genotype was showed to be related to taxanes-based chemotherapy, and its efficient rate was 23.1%, significantly lower than that of patients carrying C allele (73.5%; x2 = 9.125, P=0.003). The 3 SNPs were in linkage disequilibrium, and the 4 haplotypes TTT, TGC, CGC and TTC were 90.6 % of all. The patients who carrying 2677G-3435C haplotype showed better response to chemotherapy compared with those with the other haplotypes combined (72.1% vs 40.0%;x 2 =9.125, P=0.003). The response rate of the patients with 2677T-3435T haplotype or 1236T-3435T haplotype (54.3% or 54.9%) were lower than that of the patients harboring the other haplotypes (82.4% or 91.7%;x 2 =4.128 and x 2 =4.118, P =0.042 for both) respectively, and the efficient rate of the patients with 1236T-2677T-3435T (54.3%) were also lower than that of the patients with other haplotypes combined (82.4%;x 2 =4.128, P=0.042). Conclusion: C1236T, G2677T/A and C3435T of MDR1 gene were polymorphic with different frequency in breast cancer patients. The analyses of MDR1 C3435T genotype and its haplotypes with C1236T or G2677T/A are valuable for predicting the taxanes-based chemotherapy responses in breast cancer patients, which deserve the further study. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-21.

GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients

Genetic Polymorphisms in Glutathione S-Transferase (GST) Gene and Their Correlation with Toxicity of Chemotherapy in Breast Cancer Patients

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Effect of GSTP1 Genetic Polymorphism on Sensitivity of Platinum-Based Chemotherapy

Genetic Polymorphisms in Glutathione-S-Transferase Genes (gstm1, Gstt1, Gstp1) and Survival after Chemotherapy for Invasive Breast Carcinoma

Gene polymorphism and prediction of toxicity to platinum-based chemotherapy in patients with gynecologic cancer

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

Genetic variability of glutathione S -transferases influences treatment outcome of breast cancer

Impact of ABCB1 single‐nucleotide variants on early, extremely severe neutropenia induced by paclitaxel/nanoparticle albumin‐bound paclitaxel in patients with gastric cancer

Study on the Relationship of GSTP1(rs1695)Genetic Polymorphism with Hematological Toxicity of Autologous Hematopoietic Stem Cell Transplantation Patients

Interaction Between Glutathione S‐transferase M1‐null/present Polymorphism and Adjuvant Chemotherapy Influences the Survival of Breast Cancer

Genetic Polymorphisms of GGT1 Gene (rs8135987, Rs5751901 and Rs2017869) Are Associated with Neoadjuvant Chemotherapy Efficacy and Toxicities in Breast Cancer Patients

Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer

Relationship Between Single Nucleotide Polymorphisms and the Toxicy and Side Effects of Paclitaxel and Platinum-Based Chemotherapy in Patients with Malignant Tumors

Evaluating The Role Of Gstp1 Genetic Polymorphism (Rs1695, 313a>G) As A Predictor In Cyclophosphamide-Induced Toxicities

Study on the Polymorphisms of CYP3A5 and GSTP1 Genes in the Prediction of Short-Term Efficacy of Docetaxel Plus Thiotepa For Patients With Metastatic Breast Cancer

Transformation of Alkylating Regimen of Thiotepa into Tepa Determines the Disease Progression Through GSTP1 Gene Polymorphism for Metastatic Breast Cancer Patients Receiving Thiotepa Containing Salvage Chemotherapy

A Genome-Wide Association Study (gwas) of Docetaxel-Induced Neutropenia in Calgb 90401/60404 (Alliance)

Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

Abstract P2-09-21: Effect of MDR1 Gene Polymorphisms and Haplotypes on Taxanes-Based Chemotherapy Responses in Chinese Han Patients with Breast Cancer

Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients